The mixed Phase 2 data for MN-001 in NAFLD/hypertriglyceridemia provides a proof-of-concept signal but lacks the statistical significance needed for a near-term catalyst. Watch for details on the design and timing of the planned larger study, and for any partnership or funding announcements that could de-risk development.
Price Chart
Executive Summary
MediciNova reported Phase 2 topline results for MN-001 (tipelukast) in hypertriglyceridemia and NAFLD with T2DM. The study showed statistically significant improvements in HDL-C and HDL-P at Week 24, and a statistically significant triglyceride reduction at Week 4, but the primary Week 24 triglyceride endpoint missed statistical significance (p=0.113). The mixed efficacy signals provide a basis for further study but do not constitute a clear regulatory catalyst.
Key Facts
- Phase 2 trial (MN-001-NATG-202) enrolled 40 patients with NAFLD and hypertriglyceridemia associated with T2DM.
- Week 24 serum TG reduction: -45.8 mg/dL (21.78%) MN-001 vs -14.4 mg/dL (6.97%) placebo; difference not statistically significant (p=0.113).
- Week 4 serum TG reduction: -54.7 mg/dL (26.05%) MN-001 vs -23.8 mg/dL (11.54%) placebo; difference statistically significant (p=0.015).
- Week 24 HDL-C increased 3.3 mg/dL (8.39%) with MN-001 vs decreased 2.4 mg/dL (6.23%) with placebo; difference statistically significant (p=0.0048).
- Week 24 HDL-P increased 3.62 µmol/L (11.80%) with MN-001 vs decreased 0.9 µmol/L (3.00%) with placebo; difference statistically significant (p=0.018).
- Liver fat (CAP score) and body weight showed numerical trends favoring MN-001 but were not statistically significant.
- No drug-related serious adverse events reported; safety profile favorable.
- Company plans further analyses and a larger study to evaluate efficacy.
Financial Impact
No financial figures provided; clinical-stage biotech with no approved products or revenue.
Risk Factors
- Primary endpoint (Week 24 TG reduction) missed statistical significance, reducing confidence in the drug's efficacy.
- Small sample size (40 patients) limits generalizability and increases risk of failure in larger trials.
- No revenue or near-term approval path; company relies on funding and partnerships for continued development.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3369686 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 29d ago | Press Release | $2.10 $1.40 | ▼ −33.33% | ▼ −33.30% | $1.41 (−32.86%) |
Sep 24, 2026 4w ago | Press Release | $2.65 $1.41 | ▼ −46.79% | ▼ −46.37% | $1.41 (−46.79%) |
Sep 2, 2026 7w ago | 8-K | $1.43 $1.68 | ▲ +17.48% | ▲ +17.57% | $1.41 (−1.40%) |
Aug 19, 2026 9w ago | 8-K | $1.38 $3.45 | ▲ +150.00% | ▲ +151.95% | $1.41 (+2.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers